Sanofi recognized by S&P as one of the most
sustainability-committed companies
Sanofi recognized by S&P as one of the most
sustainability-committed companies
Paris, March
8, 2022. Sanofi was today
recognized as one of the most sustainability-committed companies in
an ESG Evaluation (Environment, Social, Governance) performed by
Standard & Poor’s Global Ratings (S&P).
The ESG Evaluation awarded Sanofi a score of 86
out of 100 points, one of the highest scores across all sectors
globally. Sanofi’s ESG profile was awarded 80 points for its solid
fundamentals, completed with an additional strong preparedness
opinion of 6 points awarded for its ‘excellent awareness of risks
and opportunities’ and its capacity to ‘anticipate and adapt to a
variety of long-term plausible disruptions’.
Sanofi's Social Profile was ranked as ‘leading’
in the category of communities highlighting the recent 2021
creation of its global health unit which aims to provide 30 of
Sanofi's medicines across a wide range of therapeutic areas to
patients in 40 of the lowest income countries. The report also
noted Sanofi’s commitment to eliminating infectious disease such as
polio, sleeping sickness and malaria.
Sanofi is the first large biopharmaceutical
company evaluated by a S&P Global Ratings ESG Evaluation and
was notably distinguished for its commitment to access to
medicines, particularly in vulnerable communities. The study, which
recognized ‘the increasing challenges and inequalities in
healthcare across all geographies’, identified the creation of a
nonprofit unit dedicated to provide poorest countries with access
to essential medicines as ‘one of Sanofi's leading
differentiators’.
Sandrine Bouttier-StrefGlobal
Head of Corporate Social Responsibility of Sanofi“We are pleased
that S&P’s Global Ratings ranked us among the topmost
sustainable companies. The results of the ESG Evaluation is true
recognition for the accomplishments that our team has achieved
since launching our ‘renewed commitment to society’ in 2021. We are
particularly proud that our newly formed Global Health Unit, which
reflects our commitment to society and vulnerable populations, has
been named as a leading differentiator by S&P Global Ratings
ESG evaluators.”
Standard & Poor’s Global
RatingsESG Evaluation“The ESG Evaluation reflects our
assessment of Sanofi's innovation capacity, which we think will
help drive the industry forward, as well as the concrete steps it
has already taken in implementing its strategy.”
Embedded into the company’s Play to Win
strategy, Sanofi’s social impact strategy is based on four
essential pillars in which Sanofi is uniquely positioned to make a
difference: (1) global access & affordability to health while
helping healthcare systems' sustainability including educational
programs, (2) Innovation for the most vulnerable populations (3)
Ensuring patients’ access to medicines while reconnecting health
with the planet (4) Building an inclusive workplace while engaging
with communities.
The continuous implementation of Sanofi’s social
impact strategy has led in recent months to a range of positive
updates of the company’s rank or grade in most of the ESG
rankings.
Sanofi communicates on a quarterly basis on the
progress on implementation of its social impact strategy with a
dedicated section in the earnings press release.
About the
ESG EvaluationS&P Global Ratings' ESG
Evaluation is a cross-sector, relative analysis of an entity's
capacity tocontinue to operate successfully. It is grounded in how
ESG factors could affect stakeholders,potentially leading to a
material direct or indirect financial impact on the entity.First,
an ESG profile is established for a given entity, which assesses
the exposure of the entity'soperations to observable ESG risks and
opportunities, and how the entity is mitigating these risks and
capitalizing on these opportunities.Second, the entity's long-term
preparedness is assessed, namely its capacity to anticipate
andadapt to a variety of long-term plausible disruptions.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69
36 93 | arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comPriya Nanduri | +1
908 981 5560 | priya.nanduri@sanofi.com Nathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2021. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024